Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ibstock holds guidance after Q1 trading improves

(Sharecast News) - Specialist brick maker Ibstock held annual guidance after trading conditions improved in the first quarter, reflecting increased demand in new build residential construction and a relatively weak comparative in 2024. Sales volumes and revenues across its core business were in line with expectations and well above the prior year, the company said in a trading statement on Wednesday.

The firm, a specialist manufacturer of clay bricks and concrete products, has been hit hard by the downturn in the building sector.

"Whilst we have seen a more competitive pricing environment in some areas of the market, we continue to take a disciplined approach to pricing," Ibstock said.

"We have started to capture the benefit of price increases initiated towards the end of the first quarter although, with market recovery more pronounced in new build residential markets, selling prices in the period were adversely impacted by sales mix."

First-quarter core earnings margins were down year on year due to the impact of cost inflation ahead of pricing action, sales mix and additional costs invested in its factory network.

"Whilst we remain mindful of broader macroeconomic uncertainties, our full year expectations are unchanged, with performance, as anticipated, weighted towards the second half."

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.